NantKwest Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
NantKwest (NK) IPO Opens Up 48%
July 28, 2015 10:38 AM EDTToday's IPO for NantKwest (NASDAQ: NK) opened for trading at $37 after pricing 8,288,000 shares of its common stock at a price to the public of $25 per share, above the expected $20-$23 range. The offering size was raised from 7,000,000 shares.
BofA Merrill Lynch, Citigroup Global Markets Inc., Jefferies LLC and Piper Jaffray are acting as joint book-running managers for the offering, and MLV & Co. LLC is acting as co-manager.
NantKwest is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat... More
NantKwest (NK) IPO Prices at $25, Above Expected Range
July 28, 2015 8:17 AM EDTNantKwest (NASDAQ: NK) announced today the pricing of its initial public offering of 8,288,000 shares of its common stock at a price to the public of $25.00 per share, above the expected $20-$23 range. Shares are expected to begin trading today on the NASDAQ under the... More
